Yahoo · Jul 15, 2026
Is This the Right Time to Hold MYGN Stock in Your Portfolio?
Myriad Genetics expands its testing portfolio and advances its Cancer Care Continuum strategy. Can reimbursement risks and cost pressures temper growth?
PA
NYSE · PAHC
Phibro Animal Health Corporation
Healthcare · Drug Manufacturers - Specialty & Generic
$34.06
Up+$0.30 (+0.88%)
Updated Aug 14, 2026, 11:01 PM
SID Score
4.7/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.65B
- P/E ratio
- 24.36
- Dividend yield
- 1.41%
- 52-week range
- $28.25 – $60.08
- Volume
- 128.89K
- Avg. volume
- 292.23K
Price performance
PAHC price history
1M range · 0 trading sessions · Daily adjusted prices
PAHC does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest PAHC news
The latest Smart Investors Daily articles mentioning PAHC.
Stock researchCompany · Overview
PAHC research
Overview
Company profile and research snapshot.
Company profile
Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $34.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 14, 2026 | Citigroup | Neutral | — |
| Apr 15, 2026 | Citigroup | Neutral | — |
| Nov 7, 2025 | JP Morgan | Overweight | — |
| Aug 29, 2025 | B of A Securities | Underperform | — |
| Jul 7, 2025 | JP Morgan | Overweight | — |
News briefing
No generated briefing is available yet.
Yahoo · Jul 9, 2026
PAHC or LZAGY: Which Is the Better Value Stock Right Now?
PAHC vs. LZAGY: Which Stock Is the Better Value Option?
Yahoo · Jul 9, 2026
Phibro Animal Health (PAHC) Leaves Russell Indexes, Is The Stock A Bargain?
Index removal puts Phibro Animal Health in a different spotlight Phibro Animal Health (PAHC) was recently removed from several Russell indices, including the Russell 3000E and Microcap benchmarks. This type of change can alter how certain institutional investors gain exposure to the stock. Index changes like this can trigger adjustments by funds that track or reference those benchmarks. They do not, however, directly affect Phibro Animal Health’s operations, revenue sources, or long history...
Yahoo · Jul 9, 2026
Phibro Animal Health (PAHC) Stock Looks Reasonable On Value But Stretched After 138% Gain
Phibro Animal Health stock has quietly posted a very large 3 year gain while still screening as undervalued on broader checks, leaving investors weighing a strong share price run against a set of metrics that point to remaining value support. Over the past 3 years, Phibro Animal Health has returned about 137.7%, which puts recent short term moves into the context of a very strong multi year run. Expectations around the company’s ability to sustain and grow cash flows from its animal health...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
